Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Invion ( (AU:IVX) ) has shared an update.
Invion Limited has announced a change in its registered office address to Suite 2, Level 11, 385 Bourke Street, Melbourne VIC 3000. This relocation is part of the company’s operational updates, while its contact details remain unchanged. This move reflects Invion’s ongoing efforts to optimize its business operations and maintain its strategic positioning in the life-science industry, particularly in the development of its innovative Photosoft™ technology.
More about Invion
Invion is a life-science company specializing in the research and development of Photosoft™ technology for treating various cancers, atherosclerosis, and infectious diseases. The company holds exclusive licensing and distribution rights for this technology in Australia, New Zealand, and several regions in Asia and Oceania. Invion is listed on the ASX and collaborates with RMW Cho Group Limited for funding research and clinical trials.
YTD Price Performance: -66.07%
Average Trading Volume: 104,204
Technical Sentiment Signal: Sell
Current Market Cap: A$8.05M
Learn more about IVX stock on TipRanks’ Stock Analysis page.